Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.

Zippe C, Pandrangi L, Agarwal A.

J Urol. 1999 Jan;161(1):62-5.

PMID:
10037369
2.

Urinary markers of bladder carcinoma.

Dey P.

Clin Chim Acta. 2004 Feb;340(1-2):57-65. Review.

PMID:
14734196
3.

[Urinary tumor marker for urothelial cancer].

Ohtani M, Iwasaki A, Shiraiwa H.

Gan To Kagaku Ryoho. 2001 Nov;28(12):1933-7. Review. Japanese.

PMID:
11729491
4.

New methods for detection of bladder cancer.

Grossman HB.

Semin Urol Oncol. 1998 Feb;16(1):17-22. Review.

PMID:
9508078
5.

NMP22 BladderChek Test: point-of-care technology with life- and money-saving potential.

Tomera KM.

Expert Rev Mol Diagn. 2004 Nov;4(6):783-94. Review.

PMID:
15525221
6.

Urine based markers of urological malignancy.

Konety BR, Getzenberg RH.

J Urol. 2001 Feb;165(2):600-11. Review.

PMID:
11176445
7.

[Diagnostic test for bladder cancer: the NMP22®].

Saint F, Quintens H, Roupret M, Amsellem-Ouazana D, Mazerolles C, Wallerand H, Bernardini S, Guy L, Soulié M, Pfister C; Sous-comité vessie du Comité de cancérologie de l'AFU.

Prog Urol. 2011 Apr;21(4):245-9. doi: 10.1016/j.purol.2010.09.027. Epub 2011 Jan 7. Review. French.

PMID:
21482397
8.

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.

Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L.

Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040. Review.

9.

[Tumor marker tests in bladder cancer].

Feil G, Stenzl A.

Actas Urol Esp. 2006 Jan;30(1):38-45. Review. Spanish.

PMID:
16703728
10.

Urinary telomerase and its possible role as a marker for bladder cancer.

Droller MJ, Kavaler E, Landman J, Liu BC.

Keio J Med. 1998 Sep;47(3):135-41. Review.

11.

NMP-22 for bladder cancer screening and surveillance.

Gray M, Sims TW.

Urol Nurs. 2004 Jun;24(3):171-2, 177-9, 186. Review.

PMID:
15311485
12.

Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.

Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF, Zlotta AR.

Eur Urol. 2011 Sep;60(3):484-92. doi: 10.1016/j.eururo.2011.05.053. Epub 2011 Jun 12. Review.

PMID:
21684071
13.

The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients.

Stonehill WH, Goldman HB, Dmochowski RR.

J Urol. 1997 Jun;157(6):2112-4. Review.

PMID:
9146593
14.

Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review.

Ku JH, Godoy G, Amiel GE, Lerner SP.

BJU Int. 2012 Sep;110(5):630-6. doi: 10.1111/j.1464-410X.2011.10884.x. Epub 2012 Feb 21. Review.

15.

Non-invasive urine based tests for the detection of bladder cancer.

Wadhwa N, Jatawa SK, Tiwari A.

J Clin Pathol. 2012 Nov;65(11):970-5. doi: 10.1136/jclinpath-2012-200812. Epub 2012 Jun 9. Review.

PMID:
22685259
16.

Defining the role of NMP22 in bladder cancer surveillance.

Nguyen CT, Jones JS.

World J Urol. 2008 Feb;26(1):51-8. Epub 2007 Dec 4. Review.

PMID:
18058108
17.

Bladder cancer screening.

Kryger JV, Messing E.

Semin Oncol. 1996 Oct;23(5):585-97. Review.

PMID:
8893869
18.

Bladder tumor markers: need, nature and application. 1. Nucleus-based markers.

Kirollos MM, McDermott S, Bradbrook RA.

Int Urogynecol J Pelvic Floor Dysfunct. 1998;9(4):221-7. Review.

PMID:
9795828
19.

Current bladder tumor tests: does their projected utility fulfill clinical necessity?

Lokeshwar VB, Soloway MS.

J Urol. 2001 Apr;165(4):1067-77. Review.

PMID:
11257640
20.

Supplemental Content

Support Center